RESUMEN
TRPV3 is a nonselective cation channel activated by temperatures above 33°C and is reported to be localized in keratinocytes and nervous tissue. To investigate a role for TRPV3 in pain modulation, we conducted a series of in vivo electrophysiological studies on spinal and brain nociceptive neurons. Structurally diverse TRPV3 receptor antagonists reduced responses of spinal wide dynamic range (WDR) neurons to low-intensity mechanical stimulation in neuropathic rats, but only CNS-penetrant antagonists decreased elevated spontaneous firing. Injections of an antagonist into the neuronal receptive field, into the L5 dorsal root ganglion, or intracerebroventricularly (ICV) attenuated the evoked firing, but only ICV injections reduced spontaneous activity. Intraspinal injections did not affect either. Spinal transection blocked the effect on spontaneous but not evoked firing after systemic delivery of a TRPV3 antagonist. Systemic administration of an antagonist to neuropathic rats also impacted the firing of On- and Off-cells in the rostral ventromedial medulla in a manner consistent with dampening nociceptive signaling. An assessment of nonevoked "pain," an EEG-measured pain-induced sleep disturbance induced by hind paw injections of CFA, was also improved with CNS-penetrant TRPV3 antagonists but not by an antagonist with poor CNS penetration. Antagonism of TRPV3 receptors modulates activity of key classes of neurons in the pain pathway in a manner consistent with limiting pathological nociceptive signaling and was mediated by receptors in the periphery and brain. Blockade of TRPV3 receptors is likely an effective means to alleviate mechanical allodynia and nonevoked pain. However, the latter will only be obtained by blocking supraspinal TRPV3 receptors.NEW & NOTEWORTHY Recent studies have linked TRPV3 to pain modulation, and much of this work has focused on its role in the skin-primary afferent interface. In this electrophysiological study, we demonstrate that receptor antagonists modulate evoked signals through peripheral mechanisms but blockade of supraspinal TRPV3 receptors contributes to dampening both evoked and nonevoked "pain" through descending modulation. Thus, the full therapeutic potential of TRPV3 antagonists may only be realized with the ability to access receptors in the brain.
Asunto(s)
Encéfalo/metabolismo , Ganglios Espinales/metabolismo , Dolor Nociceptivo/metabolismo , Nociceptores/metabolismo , Médula Espinal/metabolismo , Canales Catiónicos TRPV/metabolismo , Potenciales de Acción/efectos de los fármacos , Potenciales de Acción/fisiología , Analgésicos no Narcóticos/química , Analgésicos no Narcóticos/farmacología , Animales , Encéfalo/efectos de los fármacos , Modelos Animales de Enfermedad , Ganglios Espinales/efectos de los fármacos , Masculino , Moduladores del Transporte de Membrana/química , Moduladores del Transporte de Membrana/farmacología , Nocicepción/efectos de los fármacos , Nocicepción/fisiología , Dolor Nociceptivo/tratamiento farmacológico , Nociceptores/efectos de los fármacos , Ratas Sprague-Dawley , Sueño/efectos de los fármacos , Sueño/fisiología , Médula Espinal/efectos de los fármacos , Canales Catiónicos TRPV/antagonistas & inhibidores , Técnicas de Cultivo de TejidosRESUMEN
An efficient asymmetric synthesis of dipyridyl TRPV3 antagonist 1 is reported. The four-step route involves two C-C bond-forming steps, a highly diastereoselective alkene hydration, and asymmetric ketone hydrosilylation in 97% ee.
Asunto(s)
Canales Catiónicos TRPV/antagonistas & inhibidores , Espectroscopía de Resonancia Magnética con Carbono-13 , Humanos , Espectroscopía de Protones por Resonancia Magnética , Piridinas/química , Espectrometría de Masa por Ionización de Electrospray , EstereoisomerismoRESUMEN
Transient receptor potential vanilloid 3 (TRPV3) is a Ca(2+)- and Na(+)-permeable channel with a unique expression pattern. TRPV3 is found in both neuronal and non-neuronal tissues, including dorsal root ganglia, spinal cord, and keratinocytes. Recent studies suggest that TRPV3 may play a role in inflammation, pain sensation, and skin disorders. TRPV3 studies have been challenging, in part due to a lack of research tools such as selective antagonists. Herein, we provide the first detailed report on the development of potent and selective TRPV3 antagonists featuring a pyridinyl methanol moiety. Systematic optimization of pharmacological, physicochemical, and ADME properties of original lead 5a resulted in identification of a novel and selective TRPV3 antagonist 74a, which demonstrated a favorable preclinical profile in two different models of neuropathic pain as well as in a reserpine model of central pain.
Asunto(s)
Ciclobutanos/síntesis química , Ciclobutanos/farmacología , Piridinas/síntesis química , Piridinas/farmacología , Canales Catiónicos TRPV/antagonistas & inhibidores , Calcio/metabolismo , Ciclobutanos/química , Relación Dosis-Respuesta a Droga , Células HEK293 , Humanos , Conformación Molecular , Piridinas/química , Relación Estructura-Actividad , Canales Catiónicos TRPV/metabolismoRESUMEN
Transient receptor potential vanilloid 1 (TRPV1) is a multifunctional ion channel playing important roles in a numerous biological processes including the regulation of body temperature. Within distinct and tight chemical space of chromanyl ureas TRPV1 ligands were identified that exhibit distinctive pharmacology and a spectrum of thermoregulatory effects ranging from hypothermia to hyperthermia. The ability to manipulate these effects by subtle structural modifications of chromanyl ureas may serve as a productive approach in TRPV1 drug discovery programs addressing either side effect or desired target profiles of the compounds. Because chromanyl ureas in the TRPV1 context are generally antagonists, we verified observed partial agonist effects of a subset of compounds within that chemotype by comparing the in vitro profile of Compound 3 with known partial agonist 5'-I-RTX.
RESUMEN
The synthesis and characterization of a series of selective, orally bioavailable 1-(chroman-4-yl)urea TRPV1 antagonists is described. Whereas first-generation antagonists that inhibit all modes of TRPV1 activation can elicit hyperthermia, the compounds disclosed herein do not elevate core body temperature in preclinical models and only partially block acid activation of TRPV1. Advancing the SAR of this series led to the eventual identification of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442, 52), an analogue that possesses excellent pharmacological selectivity, has a favorable pharmacokinetic profile, and demonstrates good efficacy against osteoarthritis pain in rodents.
Asunto(s)
Analgésicos/química , Temperatura Corporal/efectos de los fármacos , Canales Catiónicos TRPV/antagonistas & inhibidores , Urea/química , Analgésicos/farmacocinética , Analgésicos/farmacología , Animales , Área Bajo la Curva , Temperatura Corporal/fisiología , Perros , Relación Dosis-Respuesta a Droga , Descubrimiento de Drogas , Células HEK293 , Humanos , Isoquinolinas/química , Isoquinolinas/farmacocinética , Isoquinolinas/farmacología , Tasa de Depuración Metabólica , Modelos Químicos , Estructura Molecular , Ratas , Relación Estructura-Actividad , Canales Catiónicos TRPV/química , Canales Catiónicos TRPV/metabolismo , Urea/análogos & derivados , Urea/farmacocinética , Urea/farmacologíaRESUMEN
The transient receptor potential vanilloid-1 (TRPV1) channel is involved in the development and maintenance of pain and participates in the regulation of temperature. The channel is activated by diverse agents, including capsaicin, noxious heat (≥ 43°C), acidic pH (< 6), and endogenous lipids including N-arachidonoyl dopamine (NADA). Antagonists that block all modes of TRPV1 activation elicit hyperthermia. To identify efficacious TRPV1 antagonists that do not affect temperature antagonists representing multiple TRPV1 pharmacophores were evaluated at recombinant rat and human TRPV1 channels with Ca(2+) flux assays, and two classes of antagonists were identified based on their differential ability to inhibit acid activation. Although both classes of antagonists completely blocked capsaicin- and NADA-induced activation of TRPV1, select compounds only partially inhibited activation of the channel by protons. Electrophysiology and calcitonin gene-related peptide release studies confirmed the differential pharmacology of these antagonists at native TRPV1 channels in the rat. Comparison of the in vitro pharmacological properties of these TRPV1 antagonists with their in vivo effects on core body temperature confirms and expands earlier observations that acid-sparing TRPV1 antagonists do not significantly increase core body temperature. Although both classes of compounds elicit equivalent analgesia in a rat model of knee joint pain, the acid-sparing antagonist tested is not effective in a mouse model of bone cancer pain.
Asunto(s)
Temperatura Corporal/efectos de los fármacos , Canales Catiónicos TRPV/antagonistas & inhibidores , Analgésicos/farmacología , Animales , Péptido Relacionado con Gen de Calcitonina/metabolismo , Calcio/metabolismo , Capsaicina/farmacología , Línea Celular Transformada , Fiebre/tratamiento farmacológico , Fiebre/fisiopatología , Células HEK293 , Humanos , Masculino , Ratones , Ratones Endogámicos C3H , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Dolor/tratamiento farmacológico , Dolor/metabolismo , Dolor/fisiopatología , Protones , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes/antagonistas & inhibidores , Proteínas Recombinantes/metabolismo , Canales Catiónicos TRPV/metabolismoRESUMEN
Despite the increasing interest in TRPA1 channel as a pain target, its role in cold sensation and body temperature regulation is not clear; the efficacy and particularly side effects resulting from channel blockade remain poorly understood. Here we use a potent, selective, and bioavailable antagonist to address these issues. A-967079 potently blocks human (IC(50): 51 nmol/L, electrophysiology, 67 nmol/L, Ca(2+) assay) and rat TRPA1 (IC(50): 101 nmol/L, electrophysiology, 289 nmol/L, Ca(2+) assay). It is >1000-fold selective over other TRP channels, and is >150-fold selective over 75 other ion channels, enzymes, and G-protein-coupled receptors. Oral dosing of A-967079 produces robust drug exposure in rodents, and exhibits analgesic efficacy in allyl isothiocyanate-induced nocifensive response and osteoarthritic pain in rats (ED(50): 23.2 mg/kg, p.o.). A-967079 attenuates cold allodynia produced by nerve injury but does not alter noxious cold sensation in naive animals, suggesting distinct roles of TRPA1 in physiological and pathological states. Unlike TRPV1 antagonists, A-967079 does not alter body temperature. It also does not produce locomotor or cardiovascular side effects. Collectively, these data provide novel insights into TRPA1 function and suggest that the selective TRPA1 blockade may present a viable strategy for alleviating pain without untoward side effects.
Asunto(s)
Regulación de la Temperatura Corporal/efectos de los fármacos , Canales de Calcio/metabolismo , Frío/efectos adversos , Hiperalgesia/tratamiento farmacológico , Proteínas del Tejido Nervioso/antagonistas & inhibidores , Proteínas del Tejido Nervioso/metabolismo , Dolor/fisiopatología , Sensación/fisiología , Canales de Potencial de Receptor Transitorio/antagonistas & inhibidores , Canales de Potencial de Receptor Transitorio/metabolismo , Animales , Presión Sanguínea/efectos de los fármacos , Presión Sanguínea/fisiología , Temperatura Corporal/efectos de los fármacos , Temperatura Corporal/fisiología , Regulación de la Temperatura Corporal/genética , Regulación de la Temperatura Corporal/fisiología , Péptido Relacionado con Gen de Calcitonina/metabolismo , Calcio/metabolismo , Canales de Calcio/genética , Células Cultivadas , Modelos Animales de Enfermedad , Interacciones Farmacológicas , Ganglios Espinales/patología , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/fisiología , Humanos , Hiperalgesia/fisiopatología , Concentración 50 Inhibidora , Isotiocianatos/farmacología , Imagen por Resonancia Magnética/métodos , Masculino , Ratones , Proteínas del Tejido Nervioso/genética , Neuronas/efectos de los fármacos , Oximas/farmacología , Oximas/uso terapéutico , Dolor/tratamiento farmacológico , Dolor/genética , Dolor/metabolismo , Dimensión del Dolor/métodos , Ratas , Ratas Sprague-Dawley , Tiempo de Reacción/efectos de los fármacos , Sensación/efectos de los fármacos , Umbral Sensorial/efectos de los fármacos , Canal Catiónico TRPA1 , Canales Catiónicos TRPV/genética , Canales Catiónicos TRPV/metabolismo , Canales de Potencial de Receptor Transitorio/genética , TritioRESUMEN
Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.
Asunto(s)
Cromanos , Quinolinas , Canales Catiónicos TRPV/antagonistas & inhibidores , Urea/farmacología , Cromanos/síntesis química , Cromanos/química , Cromanos/farmacología , Humanos , Concentración 50 Inhibidora , Estructura Molecular , Quinolinas/química , Urea/síntesis química , Urea/químicaRESUMEN
The synthesis and structure-activity relationships of a series of 5-monosubstituted and 4,5-disubstituted 2-arylaminooxazoles as novel antagonists of the transient receptor potential vanilloid 1 (TRPV1) receptor are described. The 7-hydroxy group of the tetrahydronaphthyl moiety on the 2-amino substituent of the oxazole ring was important for obtaining excellent in vitro potency at the human TRPV1 receptor, while a variety of alkyl and phenyl substituents at the 4- and 5-positions of the oxazole ring were well tolerated and yielded potent TRPV1 antagonists. Despite excellent in vitro potency, the 5-monosubstituted compounds suffered from poor pharmacokinetics. It was found that 4,5-disubstitution on the oxazole ring was critical to the improvement of the overall pharmacokinetic profile of these analogues, which led to the discovery of compound (R)-27, a novel TRPV1 antagonist with good oral activity in preclinical animal models of pain.
Asunto(s)
Naftoles/síntesis química , Oxazoles/química , Canales Catiónicos TRPV/antagonistas & inhibidores , Línea Celular , Cristalografía por Rayos X , Humanos , Conformación Molecular , Naftoles/química , Naftoles/farmacocinética , Oxazoles/síntesis química , Oxazoles/farmacocinética , Canales Catiónicos TRPV/metabolismoRESUMEN
A series of 1,2,3,6-tetrahydropyridyl-4-carboxamides, exemplified by 6, have been synthesized and evaluated for in vitro TRPV1 antagonist activity, and in vivo analgesic activity in animal pain models. The tetrahydropyridine 6 is a novel TRPV1 receptor antagonist that potently inhibits receptor-mediated Ca2+ influx in vitro induced by several agonists, including capsaicin, N-arachidonoyldopamine (NADA), and low pH. This compound penetrates the CNS and shows potent anti-nociceptive effects in a broad range of animal pain models upon oral dosing due in part to its ability to antagonize both central and peripheral TRPV1 receptors. The SAR leading to the discovery of 6 is presented in this report.
Asunto(s)
Analgésicos/farmacología , Piridinas/administración & dosificación , Canales Catiónicos TRPV/antagonistas & inhibidores , Administración Oral , Analgésicos/síntesis química , Animales , Ácidos Araquidónicos/farmacología , Calcio/metabolismo , Capsaicina/farmacología , Modelos Animales de Enfermedad , Dopamina/análogos & derivados , Dopamina/farmacología , Relación Dosis-Respuesta a Droga , Concentración de Iones de Hidrógeno , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/metabolismo , Hiperalgesia/patología , Dimensión del Dolor , Piridinas/síntesis química , Piridinas/farmacología , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad , Canales Catiónicos TRPV/metabolismoRESUMEN
Vanilloid receptor TRPV1 is a cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation by several pharmaceutical companies in an effort to identify novel agents for pain management. Here we report that replacement of substituted benzyl groups by an indan rigid moiety in a previously described N-indazole- N'-benzyl urea series led to a number of TRPV1 antagonists with significantly increased in vitro potency and enhanced drug-like properties. Extensive evaluation of pharmacological, pharmacokinetic, and toxicological properties of synthesized analogs resulted in identification of ( R)-7 ( ABT-102). Both the analgesic activity and drug-like properties of ( R)-7 support its advancement into clinical pain trials.
Asunto(s)
Analgésicos/síntesis química , Indazoles/síntesis química , Indenos/síntesis química , Canales Catiónicos TRPV/antagonistas & inhibidores , Urea/análogos & derivados , Urea/síntesis química , Administración Oral , Analgésicos/farmacocinética , Analgésicos/farmacología , Animales , Disponibilidad Biológica , Perros , Haplorrinos , Humanos , Técnicas In Vitro , Indazoles/farmacocinética , Indazoles/farmacología , Indenos/farmacocinética , Indenos/farmacología , Microsomas Hepáticos/metabolismo , Dolor/tratamiento farmacológico , Dolor/etiología , Ratas , Estereoisomerismo , Relación Estructura-Actividad , Urea/farmacocinética , Urea/farmacologíaRESUMEN
The synthesis and structure-activity relationship of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 (TRPV1) antagonists are described. A variety of cyclic amine substituents are well tolerated at the 4-position of the benzyl group on compounds containing either an isoquinoline or indazole heterocyclic core. These compounds are potent antagonists of capsaicin activation of the TRPV1 receptor in vitro. Analogues, such as compound 45, have been identified that have good in vivo activity in animal models of pain. Further optimization of 45 resulted in compound 58 with substantially improved microsome stability and oral bioavailability, as well as in vivo activity.
Asunto(s)
Analgésicos/síntesis química , Indazoles/síntesis química , Compuestos de Fenilurea/síntesis química , Canales Catiónicos TRPV/antagonistas & inhibidores , Urea/análogos & derivados , Administración Oral , Analgésicos/farmacocinética , Analgésicos/farmacología , Animales , Disponibilidad Biológica , Perros , Estabilidad de Medicamentos , Humanos , Técnicas In Vitro , Indazoles/farmacocinética , Indazoles/farmacología , Isoquinolinas/síntesis química , Isoquinolinas/farmacocinética , Isoquinolinas/farmacología , Microsomas Hepáticos/metabolismo , Compuestos de Fenilurea/farmacocinética , Compuestos de Fenilurea/farmacología , Ratas , Relación Estructura-Actividad , Urea/síntesis química , Urea/farmacocinética , Urea/farmacologíaRESUMEN
Novel 5,6-fused heteroaromatic ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that 4-aminoindoles and indazoles are the preferential cores for the attachment of ureas. Bulky electron-withdrawing groups in the para-position of the aromatic ring of the urea substituents imparted the best in vitro potency at TRPV1. The most potent derivatives were assessed in in vivo inflammatory and neuropathic pain models. Compound 46, containing the indazole core and a 3,4-dichlorophenyl group appended to it via a urea linker, demonstrated in vivo analgesic activity upon oral administration. This derivative also showed selectivity versus other receptors in the CEREP screen and exhibited acceptable cardiovascular safety at levels exceeding the therapeutic dose.
Asunto(s)
Canales Catiónicos TRPV/antagonistas & inhibidores , Urea/análogos & derivados , Animales , Técnicas In Vitro , Cinética , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Dimensión del Dolor , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad , Canales Catiónicos TRPV/metabolismo , Urea/síntesis química , Urea/química , Urea/farmacologíaRESUMEN
Novel transient receptor potential vanilloid 1 (TRPV1) receptor antagonists with various bicyclic heteroaromatic pharmacophores were synthesized, and their in vitro activity in blocking capsaicin activation of TRPV1 was assessed. On the basis of the contribution of these pharmacophores to the in vitro potency, they were ranked in the order of 5-isoquinoline > 8-quinoline = 8-quinazoline > 8-isoquinoline > or = cinnoline approximately phthalazine approximately quinoxaline approximately 5-quinoline. The 5-isoquinoline-containing compound 14a (hTRPV1 IC50 = 4 nM) exhibited 46% oral bioavailability and in vivo activity in animal models of visceral and inflammatory pain. Pharmacokinetic and pharmacological properties of 14a are substantial improvements over the profile of the high-throughput screening hit 1 (hTRPV1 IC50 = 22 nM), which was not efficacious in animal pain models and was not orally bioavailable.